Zhang Jing-Shun, Sun Yuan-Dong, Li Yuan-Min, Han Jian-Jun
Department of Thoracic Surgery, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji'nan, Shandong, China.
Department of Interventional Radiology, Shandong Cancer Hospital and Institute Affiliated Shandong First Medical University and Shandong Academy of Medical Sciences, Ji'nan, Shandong, China.
Heliyon. 2024 Aug 14;10(16):e36388. doi: 10.1016/j.heliyon.2024.e36388. eCollection 2024 Aug 30.
This review examines combining tumor ablation therapy with immunotherapy for respiratory and digestive system tumors, particularly NSCLC and liver cancer. Despite advancements in traditional methods, they face limitations in advanced-stage tumors. Ablation techniques like RFA, MWA, and cryoablation offer minimally invasive options, while immune checkpoint inhibitors enhance the immune system's tumor-fighting ability. This review highlights their synergistic effects, clinical outcomes, and future research directions, including optimizing protocols, exploring new combinations, uncovering molecular mechanisms, advancing precision medicine, and improving accessibility. Combined therapy is expected to improve efficacy and patient outcomes significantly.
本综述探讨了将肿瘤消融疗法与免疫疗法联合用于呼吸系统和消化系统肿瘤，特别是非小细胞肺癌和肝癌。尽管传统方法取得了进展，但它们在晚期肿瘤方面存在局限性。射频消融（RFA）、微波消融（MWA）和冷冻消融等消融技术提供了微创选择，而免疫检查点抑制剂则增强了免疫系统对抗肿瘤的能力。本综述强调了它们的协同效应、临床结果和未来研究方向，包括优化方案、探索新的联合方式、揭示分子机制、推进精准医学以及提高可及性。联合治疗有望显著提高疗效和患者预后。
